McNicoll, Lewis & Vlak reiterated its Alnylam Pharmaceuticals ALNY Buy rating and $15 price target in a research report published today.
In the report, McNicoll, Lewis & Vlak states, "In our opinion, RNAi represents the next major therapeutic class; it has the potential to transform the biotechnology and pharmaceutical industries, similar to the transformation made by both recombinant DNA and monoclonal antibodies."
Shares of Alnylam Pharmaceuticals were trading at $9.37 at the time of posting, down 0.74% from Friday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in